Ubiquigent company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.



Unattributed VC | Alive

Total Raised


About Ubiquigent

Ubiquigent develops and provides a range of reagents, kits, assay development, drug lead compound profiling (including DUBprofiler for profiling deubiquitylase enzyme inhibitors) and other services. These products and services support academic and pharmaceutical researchers to understand the role of protein ubiquitylation in regulating many aspects of cellular functions and the development and optimization of drug candidate compounds that target the system addressing a number of critical therapeutic areas.

Ubiquigent Headquarter Location

Sir James Black Centre Dow Street

Dundee, Scotland, DD1 5EH,

United Kingdom

+1 617 245 0020

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ubiquigent

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ubiquigent is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Ubiquigent News

Ubiquigent celebrates milestone anniversary of DUBprofiler™ compound profiling platform

Dec 14, 2021

December 14, 2021 09:00 AM Eastern Standard Time DUNDEE, Scotland--( BUSINESS WIRE )--Today, Ubiquigent Limited (Ubiquigent) celebrates the 10th anniversary of its DUBprofiler™ compound profiling platform, together with KSQ Therapeutics joining its expanding customer base. Over the last 10 years Ubiquigent has profiled thousands of compounds across hundreds of studies on behalf of research groups located within pharma and biotech companies as well as many academic institutions. These groups share the common goal of seeking to identify novel deubiquitylase (DUB) enzyme inhibitors as potential new therapeutics. KSQ Therapeutics approached Ubiquigent to evaluate a number of its novel compounds, one of which has subsequently become the first DUB inhibitor to enter clinical development. Ubiquigent rapidly profiled KSQ’s compounds across its full DUBprofiler™ enzyme panel, demonstrating their inhibition of USP1 and selectivity profile. DUBprofiler™ is one of the most highly cited and comprehensive deubiquitylase (DUB) enzyme profiling platforms available. Its constantly expanding panel of human DUB enzymes is one of the most efficient ways to identify novel DUB inhibitors and establish their selectivity and potency. DUBprofiler™ forms a key part of Ubiquigent’s Drug Discovery Screening Platform and is typically the first step in the evaluation of potential modulators of DUBs. Once profiled, compounds can be rapidly advanced into other DUB focused cell-based assays such as DUBprofiler-Cell™ to determine compound-cellular DUB target engagement and DUB selectivity in cells, as well as into custom assays designed to address target-specific questions. Ubiquigent’s CEO, Jason Mundin commented: “This milestone anniversary for Ubiquigent is testament to those within our company who recognised the emerging need for a robust platform that could support the development of DUB-targeting compounds. We look forward to continuing to develop the DUBprofiler™ platform alongside our other capabilities to support those working in this developing field. We would also like to wish KSQ Therapeutics every success with their programme as it progresses through the clinic”. About Ubiquigent Ubiquigent Limited is a revenue- and IP-generating life sciences business that enables and supports protein degradation focused drug discovery via modulation and exploitation of the ubiquitin system. Our chemistry and biology platforms allow us to design and develop novel compounds as part of strategic partnerships. In parallel we also provide access to our platforms and capabilities for the evaluation of our partners’ compounds. For more information please visit www.ubiquigent.com . Contacts

Ubiquigent Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ubiquigent Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.